Mizuho raises Humana price target to $390
Mizuho analyst Ann Hynes maintained an Outperform rating on Humana and increased the price target to $390 from $335, signaling a positive shift in valuation outlook.
*this image is generated using AI for illustrative purposes only.
Mizuho analyst Ann Hynes has maintained an Outperform rating on Humana while raising the price target to $390 from $335. The revised target indicates a positive adjustment in the firm's valuation outlook for the healthcare company.
The rating action provides investors with a new benchmark for the stock's potential performance. The price target increase suggests a shift in the analyst's financial model or expectations regarding Humana's future earnings.
Rating and Price Target Details
The following table outlines the changes made by Mizuho:
| Metric | Previous Value | New Value |
|---|---|---|
| Rating | Outperform | Outperform |
| Price Target | $335 | $390 |
What specific factors drove Mizuho to adjust Humana's valuation model so significantly?
How might this price target increase influence other analysts' ratings on Humana?
What are the expected market reactions to this upgraded outlook in the short term?
20
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
